Similar Search Results

Organizational failure and incentive contracts in the public sector : evidence from an experiment in the financing of mental health care

Frank, Richard G.; Gaynor, Martin - 1991

Persistent link: https://www.econbiz.de/10000829593

Organizational failure and transfers in the public sector : evidence from an experiment in the financing of mental health care

Frank, Richard G. - In: Journal of human resources : JHR 29 (1994) 1, pp. 108-125

Persistent link: https://www.econbiz.de/10001167278

Demand-side factors associated with the purchase of long-term care insurance

Unruh, Mark A.; Stevenson, David G.; Frank, Richard G.; … - In: Forum for health economics & policy : an evolving … 19 (2016) 1, pp. 23-43

Persistent link: https://www.econbiz.de/10011537318

High-priced drugs in Medicare Part D : diagnosis and potential prescription

Frank, Richard G.; Zeckhauser, Richard - 2018

Persistent link: https://www.econbiz.de/10011796655

The regulation of prescription drug competition and market responses : patterns in prices and sales following loss of exclusivity

Aitken, Murray L.; Berndt, Ernst R.; Bosworth, Barry; … - In: Measuring and modeling health care costs, (pp. 243-271). 2018

Persistent link: https://www.econbiz.de/10011812699

The regulation of prescription drug competition and market responses : patterns in prices and sales following loss of exclusivity

Aitken, Murray L.; Berndt, Ernst R.; Bosworth, Barry; … - 2013

Persistent link: https://www.econbiz.de/10010198694

Long-term care financing in the United States : sources and institutions

Frank, Richard G. - In: Applied economic perspectives and policy 34 (2012) 2, pp. 333-345

Persistent link: https://www.econbiz.de/10009721586

The Regulation of Prescription Drug Competition and Market Responses : Patterns in Prices and Sales Following Loss of Exclusivity

Aitken, Murray L. - 2013

We examine six molecules facing initial loss of US exclusivity (LOE, from patent expiration or challenges) between June 2009 and May 2013 that were among the 50 most prescribed molecules in May 2013. We examine prices per day of therapy (from the perspective of average revenue received by retail...

Persistent link: https://www.econbiz.de/10012459174